1-14 of 14
Authors: Vidya Chandramohan
Journal Article
CTIM-13. D2C7-IT IN COMBINATION WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM) Free
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii87, https://doi.org/10.1093/neuonc/noae165.0346
Published: 11 November 2024
Journal Article
IMMU-11. NLRP3+ TUMOR-ASSOCIATED MYELOID CELLS ARE ENRICHED IN ASTROCYTIC GLIOMAS AND REPRESENT A THERAPEUTIC VULNERABILITY Free
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v143, https://doi.org/10.1093/neuonc/noad179.0543
Published: 10 November 2023
Journal Article
CTIM-09. PHASE 1/1B TRIAL OF FC-ENGINEERED ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (2141-V11) INFUSED WITH D2C7-IT IN ENHANCING DISEASE BY CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (RMG) Free
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v62–v63, https://doi.org/10.1093/neuonc/noad179.0249
Published: 10 November 2023
Journal Article
EPCO-50. THE TRANSCRIPTIONAL LANDSCAPE OF KEY INNATE DNA SENSORS WITHIN PRIMARY BRAIN TUMORS Free
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v135, https://doi.org/10.1093/neuonc/noad179.0512
Published: 10 November 2023
Journal Article
EXTH-39. D2C7-CAR: A NOVEL, DUAL-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL WITH HIGH SPECIFICITY FOR EGFR AND EGFRVIII IMPROVES SURVIVAL IN EGFR/EGFRVIII GLIOBLASTOMA AND EGFR OVER-EXPRESSING MEDULLOBLASTOMA Free
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v233, https://doi.org/10.1093/neuonc/noad179.0892
Published: 10 November 2023
Journal Article
CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS) Free
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii65, https://doi.org/10.1093/neuonc/noac209.255
Published: 14 November 2022
Journal Article
CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG) Free
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii38, https://doi.org/10.1093/neuonc/noaa215.157
Published: 09 November 2020
Journal Article
EPCO-21. STING PROMOTER EPIGENETIC SILENCING IN GLIOBLASTOMA Free
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii73, https://doi.org/10.1093/neuonc/noaa215.300
Published: 09 November 2020
Journal Article
ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG) Free
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Page vi6, https://doi.org/10.1093/neuonc/noz175.023
Published: 11 November 2019
Journal Article
PDTM-46. POLIOVIRUS RECEPTOR (CD155) EXPRESSION IN PEDIATRIC BRAIN TUMORS MEDIATES ONCOLYSIS OF MEDULLOBLASTOMA AND PLEOMORPHIC XANTHOASTROCYTOMA Free
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi213, https://doi.org/10.1093/neuonc/noy148.885
Published: 05 November 2018
Journal Article
ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG) Free
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi9, https://doi.org/10.1093/neuonc/noy148.031
Published: 05 November 2018
Journal Article
IMMU-21. TARGETING EGFR IN HYPOMUTATED PEDIATRIC BRAIN TUMORS USING THE D2C7 IMMUNOTOXIN Free
Neuro-Oncology, Volume 20, Issue suppl_2, June 2018, Page i103, https://doi.org/10.1093/neuonc/noy059.337
Published: 22 June 2018
Journal Article
ATIM-18. PHASE I DOSE ESCALATION STUDY OF D2C7-IT ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG) Free
Neuro-Oncology, Volume 18, Issue suppl_6, November 2016, Pages vi21–vi22, https://doi.org/10.1093/neuonc/now212.083
Published: 07 November 2016
Journal Article
IDH1 MUTATIONS AS A IMMUNOTHERAPEUTIC TARGET FOR BRAIN TUMORS Get access
Neuro-Oncology, Volume 16, Issue suppl_3, July 2014, Page iii40, https://doi.org/10.1093/neuonc/nou208.65
Published: 01 July 2014
